CLINICAL TRIALS PROFILE FOR ALCOHOL 10% AND DEXTROSE 5%

505(b)(2) Clinical Trials for Alcohol 10% And Dextrose 5%

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT00071227 ↗	Eye Injections of Triamcinolone Acetonide for Retinal Blood Vessel Disorders	Completed	National Eye Institute (NEI)	Phase 1	2003-10-15	This study will evaluate the safety and effectiveness of a new formulation of triamcinolone acetonide for the treatment of retinal blood vessel disorders. Triamcinolone is a steroid drug that decreases inflammation and scarring and is routinely used to treat eye inflammation or swelling. The commercially available form of this drug is associated with potentially harmful side effects thought to be due to preservatives in the preparation. This study will use a formulation that does not contain these potentially harmful preservatives. Preliminary findings from other studies suggest that injection of steroids in the eye can reduce retinal thickening and improve vision. However, they may also cause mild discomfort and lead to vision-threatening conditions. The effects of the drug on the conditions under study in this protocol are not known. Patients with the following conditions involving disorders of retinal blood vessels may be eligible for this study: - Choroidal neovascularization associated with age-related macular degeneration (50 years of age and older) - Macular edema associated with retinal vein occlusion (18 years of age and older) - Diabetic macular edema ((18 years of age and older) Participants undergo the following tests and procedures: - Medical history and physical examination - Eye examination to assess visual acuity (eye chart test) and eye pressure, and to examine pupils, lens, retina and eye movements. The pupils will be dilated with drops for this examination. - Fluorescein angiography to evaluate the eye's blood vessels. A yellow dye is injected into an arm vein and travels to the blood vessels in the eyes. Pictures of the retina are taken using a camera that flashes a blue light into the eye. The pictures show if any dye has leaked from the vessels into the retina, indicating possible blood vessel abnormality. - Indocyanine green angiography to identify feeder vessels that may be supplying abnormal blood vessels. This procedure is similar to fluorescein angiography, but uses a green dye and flashes an invisible light. - Optical coherence tomography to measure retinal thickness. This test shines a light into the eye and produces cross-sectional pictures of the retina. These measurements are repeated during the study to determine if retinal thickening is getting better or worse, or staying the same. - Stereoscopic color fundus photography to examine the back of the eye. The pupils are dilated with eye drops to allow examination and photography of the back of the eye. - Triamcinolone acetonide injection to treat the eye. A numbing eye drop, an antibiotic eye drop, and an injected antibiotic are put in the eye before triamcinolone acetonide is injected into the eye's vitreous (jelly-like substance inside the eye). After the injection, the patient lies on his or her back for 30 minutes. An antibiotic eye ointment is used for 2 days following treatment. - Blood tests to measure liver and kidney function. Patients return to the clinic for follow-up visits 1, 4, and 7 days, and 1 month after the first treatment. Patients whose condition does not improve after 3 months do not receive any more injections, but return for eye examinations at least once a year for 3 years. Patients whose condition improves with treatment return for follow-up visits 6 and 9 months after the first injection and then every 6 months for 2 more years. At each visit, a determination is made whether another injection is needed. After each repeat injection, patients return for follow-up visits at 1, 4, and 7 days after the injection.
New Formulation	NCT00640159 ↗	Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease	Completed	Baylor College of Medicine	Phase 4	2007-01-01	Parkinson's disease (PD) is a progressive neurodegenerative disease. Symptomatic therapy is primarily aimed at restoring dopamine function in the brain. Oral selegiline in conjunction with L-dopa has been a mainstay of therapy for PD patients experiencing motor fluctuations for many years. The mechanisms accounting for selegiline's beneficial adjunctive action in the treatment of PD are not fully understood. Inhibition of monoamine oxidase (MAO) type B (MAO-B) activity is generally considered to be of primary importance. Oral selegiline has low bio-availability and is typically dosed BID, for a total of 5-10 mg daily. Recently, the FDA approved a new orally disintegration tablet (ODT) formulation of selegiline, called ZelaparTM. This new formulation utilizes Zydis technology to dissolve in the mouth, with absorption through the oral mucosa, thereby largely bypassing the gut and avoiding first pass hepatic metabolism. This allows more active drug to be delivered at a lower dose. Consequently, Zelapar is dosed once-daily, up to 2.5 mg per day. There are no empirical data indicating whether the use of the new approved formulation of selegiline ODT (Zelapar) is superior or preferred by patients compared to traditional oral selegiline. It is believed that clinical efficacy will be preserved or enhanced, by delivering more active drug, with improved patient preference for the ODT formulation due to the once-daily dosing . The effectiveness of orally disintegrating selegiline as an adjunct to carbidopa/levodopa in the treatment of PD was established in a multicenter randomized placebo-controlled trial (n=140; 94 received orally disintegrating selegiline, 46 received placebo) of three months' duration. Patients randomized to orally disintegrating selegiline received a daily dose of 1.25 mg for the first 6 weeks and a daily dose of 2.5 mg for the last 6 weeks. Patients were all treated with levodopa and could additionally have been on dopamine agonists, anticholinergics, amantadine, or any combination of these during the trial. At 12 weeks, orally disintegrating selegiline-treated patients had an average of 2.2 hours per day less "OFF" time compared to baseline. Placebo treated patients had 0.6 hours per day less "OFF" time compared to baseline. These differences were significant (p < 0.001). Adverse events were very similar between drug and placebo.
OTC	NCT00754247 ↗	A Randomized Comparative Study Evaluating the Tolerability and Efficacy of Two Topical Therapies for the Treatment of Keloids and Hypertrophic Scars	Completed	University of Miami	Phase 4	2006-03-01	Keloids are thought to result from derailments in the typical wound healing process following cutaneous injury. Current treatment options for keloids include intralesional corticosteroids, silicone gel sheeting, compression, surgery and adjuvants to surgery, including radiation and cryotherapy. 0.5% hydrocortisone, silicone, vitamin E lotion (HSE) and onion extract gel (OE) are widely used over-the-counter medications for the treatment of keloids and hypertrophic scars. However, their efficacy and safety have not been compared in a blinded, placebo-controlled, prospective fashion. This study is being undertaken to determine the efficacy and safety of HSE versus OE versus placebo (Cetearyl alcohol; CEA) in subjects with hypertrophic scars and keloids. This is an investigator-blinded study, which means that the doctor evaluating you will not know if you are receiving the study medication or not. Another doctor will be supplying you with the medication and discussing any problems that you may have with the medication. You will be assigned to one of the three treatment groups: HSE, OE, or CEA. The group will be assigned by chance and you will have two in three chances of receiving treatment with a study medication, HSE or OE. The no treatment group will receive CEA, a bland lotion, containing no active ingredients such as steroids, silicone, vitamin E, or onion extract.
New Formulation	NCT01349140 ↗	EXPAREL Dose-Response for Single-Injection Femoral Nerve Blocks	Completed	Pacira Pharmaceuticals, Inc	Phase 1	2012-02-01	EXPAREL™, an investigational drug product, is a new formulation of a local anesthetic (numbing medicine) that is designed to be longer acting than the currently-available local anesthetics. The purpose of this study is to define the dose-response curve of EXPAREL, an investigational extended-duration formulation of the local anesthetic bupivacaine, on both motor and sensory block when applied in a fixed volume adjacent to the femoral nerve.
New Formulation	NCT01349140 ↗	EXPAREL Dose-Response for Single-Injection Femoral Nerve Blocks	Completed	University of California, San Diego	Phase 1	2012-02-01	EXPAREL™, an investigational drug product, is a new formulation of a local anesthetic (numbing medicine) that is designed to be longer acting than the currently-available local anesthetics. The purpose of this study is to define the dose-response curve of EXPAREL, an investigational extended-duration formulation of the local anesthetic bupivacaine, on both motor and sensory block when applied in a fixed volume adjacent to the femoral nerve.

All Clinical Trials for Alcohol 10% And Dextrose 5%

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000152 ↗	Randomized Trial of Beta-Carotene and Macular Degeneration	Unknown status	National Eye Institute (NEI)	Phase 3	1982-04-01	To determine whether 50 mg of beta-carotene taken every other day reduces the risk of developing age-related macular degeneration (AMD) among male U.S. physicians who were aged 40 to 84 in 1982. To investigate the possible relationship of AMD with other antioxidants, including selenium and vitamins A, C, and E. To identify potential risk factors for development of AMD. Possible risk factors include height, systemic hypertension, cardiovascular disease, blood cholesterol, cigarette smoking, iris and skin color, sunlight exposure, body mass index, diabetes, and alcohol intake.
NCT00000159 ↗	Sorbinil Retinopathy Trial (SRT)	Completed	National Eye Institute (NEI)	Phase 3	1983-08-01	To evaluate the safety and efficacy of the investigational drug sorbinil, an aldose reductase inhibitor, in preventing the development of diabetic retinopathy and neuropathy in persons with insulin-dependent diabetes.
NCT00000161 ↗	Randomized Trials of Vitamin Supplements and Eye Disease	Unknown status	National Eye Institute (NEI)	Phase 3	1993-08-01	To determine whether vitamin E supplementation reduces the risk of cataract and age-related macular degeneration (AMD) in women. To determine whether vitamin C supplementation reduces the risk of cataract and AMD in women. To determine whether beta-carotene supplementation reduces the risk of cataract and AMD in women. To determine whether alternate day, low-dose aspirin reduces the risk of cataract and AMD in women. To identify potential risk factors for cataract and AMD including cigarette smoking, alcohol intake, blood pressure, blood cholesterol, cardiovascular disease, height, body mass index, and diabetes.
NCT00000257 ↗	Effects of Alcohol History on Effects of Nitrous Oxide - 9	Completed	National Institute on Drug Abuse (NIDA)	N/A	1995-09-01	The purpose of this study is to conduct experiments to examine subjective and reinforcing effects of nitrous oxide. Mood altering and psychomotor effects will be tested on non-drug abusers and preference procedures will be used to assess reinforcing effects. Comparisons between nitrous oxide, opiates, and benzodiazepine antagonists will be made. To determine effects of alcohol history on the reinforcing, subjective and psychomotor effects of nitrous oxide in healthy volunteers.
NCT00000257 ↗	Effects of Alcohol History on Effects of Nitrous Oxide - 9	Completed	University of Chicago	N/A	1995-09-01	The purpose of this study is to conduct experiments to examine subjective and reinforcing effects of nitrous oxide. Mood altering and psychomotor effects will be tested on non-drug abusers and preference procedures will be used to assess reinforcing effects. Comparisons between nitrous oxide, opiates, and benzodiazepine antagonists will be made. To determine effects of alcohol history on the reinforcing, subjective and psychomotor effects of nitrous oxide in healthy volunteers.

Clinical Trial Conditions for Alcohol 10% And Dextrose 5%

Condition Name

Condition Name for Alcohol 10% And Dextrose 5%
Intervention	Trials
Alcohol Use Disorder	208
Alcoholism	188
Alcohol Dependence	162
Alcohol Drinking	63

Condition MeSH

Condition MeSH for Alcohol 10% And Dextrose 5%
Intervention	Trials
Alcoholism	611
Alcohol Drinking	243
Disease	189
Depression	65

Clinical Trial Locations for Alcohol 10% And Dextrose 5%

Trials by Country

Trials by Country for Alcohol 10% And Dextrose 5%
Location	Trials
United Kingdom	60
Germany	51
Egypt	46
China	46
Brazil	44

Trials by US State

Trials by US State for Alcohol 10% And Dextrose 5%
Location	Trials
California	193
Texas	142
New York	141
Connecticut	131
Maryland	125

Clinical Trial Progress for Alcohol 10% And Dextrose 5%

Clinical Trial Phase

Clinical Trial Phase for Alcohol 10% And Dextrose 5%
Clinical Trial Phase	Trials
PHASE4	27
PHASE3	29
PHASE2	63

Clinical Trial Status

Clinical Trial Status for Alcohol 10% And Dextrose 5%
Clinical Trial Phase	Trials
Completed	1161
Recruiting	336
Not yet recruiting	200

Clinical Trial Sponsors for Alcohol 10% And Dextrose 5%

Sponsor Name

Sponsor Name for Alcohol 10% And Dextrose 5%
Sponsor	Trials
National Institute on Alcohol Abuse and Alcoholism (NIAAA)	301
Yale University	105
National Institute on Drug Abuse (NIDA)	94

Sponsor Type

Sponsor Type for Alcohol 10% And Dextrose 5%
Sponsor	Trials
Other	2620
NIH	566
Industry	512

Clinical Trials Update, Market Analysis, and Projection for Alcohol 10% and Dextrose 5%

Last updated: October 30, 2025

Introduction

Alcohol 10% and Dextrose 5% are widely utilized solutions in clinical and emergency medical settings, playing vital roles in disinfection, wound care, and intravenous therapy. As healthcare providers continue to seek effective and safe formulations, innovation within this formulation space is driven by ongoing clinical trials, regulatory developments, and market dynamics. This report delivers a comprehensive update on recent clinical trials, assesses the current market landscape, and projects future trends for Alcohol 10% and Dextrose 5%.

Clinical Trials Update

Overview of Current Clinical Investigations

Recent clinical endeavors primarily focus on enhancing the safety profiles of alcohol-based disinfectants and refining dextrose solutions for parenteral nutrition. Notably, the COVID-19 pandemic intensified scrutiny of alcohol-based hand sanitizers and surface disinfectants, prompting new trials to optimize efficacy while minimizing adverse effects.

• Alcohol 10%: Clinical studies have explored its efficacy in pathogen inactivation, especially against multidrug-resistant organisms. A 2022 randomized controlled trial demonstrated that formulations with 10% alcohol exhibit comparable antimicrobial activity to higher concentrations while reducing skin irritation potential [1].

• Dextrose 5%: Multiple trials focus on its utilization in parenteral nutrition (PN), particularly in critically ill patients. Recent studies in 2021 and 2022 assess infusion stability, osmolarity, and metabolic impacts, emphasizing safety in pediatric and neonatal populations [2].

Innovative Formulations and Safety Profiles

Advancements include reformulations intended to lower alcohol evaporation rates, improve antimicrobial spectrum, and reduce adverse skin reactions. Safety data from recent trials indicate that Alcohol 10% is well tolerated when applied topically, with minimal reports of dermatitis or hypersensitivity.

Regarding Dextrose 5%, research explores its use in reducing hyperglycemia in ICU settings, with trial results suggesting that controlled infusion rates mitigate metabolic complications [3].

Regulatory and Trial Progress

Most clinical trials are conducted under rigorous oversight by agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). To date, no major clinical trial disruptions have been noted, reinforcing the stability of ongoing research efforts. Several trials are in Phase II and III stages, aiming to validate efficacy and develop new therapeutic indications, including adjunctive wound care for diabetic ulcers.

Market Analysis

Current Market Landscape

Market Size and Segments

The global market for alcohol-based disinfectants and intravenous solutions like Dextrose 5% has exhibited steady growth. According to Allied Market Research, the disinfectant segment alone was valued at approximately USD 6.4 billion in 2021, projected to reach USD 10.2 billion by 2030, with a Compound Annual Growth Rate (CAGR) of around 5.2% [4].

• Alcohol 10% solutions: Predominantly used in hospital disinfectants, hand sanitizers, and surface cleaners, with a significant share in both institutional and consumer markets. The COVID-19 pandemic accelerated demand, which remains high due to ongoing infection control practices.

• Dextrose 5% solutions: Majorly used in parenteral nutrition, with notable growth in ICU and neonatal units. The rising prevalence of chronic diseases like diabetes and malnutrition sustains long-term demand.

Geographical Insights

The North American market dominates due to stringent health regulations and high healthcare expenditure, accounting for approximately 40% of global sales. Europe follows closely, buoyed by aging populations and infection prevention priorities. The Asia-Pacific region presents the highest growth potential, driven by expanding healthcare infrastructure and increased hospitalizations in China and India.

Market Drivers and Restraints

• Drivers: Increasing infection control measures, rising prevalence of chronic diseases necessitating intravenous therapies, and technological innovations in disinfectant formulations.

• Restraints: Fluctuating raw material prices, regulatory hurdles related to safety and efficacy standards, and competition from alternative disinfectant chemicals such as chlorhexidine and quaternary ammonium compounds.

Competitive Landscape

Major players include 3M, Johnson & Johnson, Baxter International, and Abbott Laboratories. These firms are investing in R&D to develop formulations with enhanced antimicrobial efficacy, reduced skin irritation, and improved stability. Partnerships with healthcare providers and regulatory bodies facilitate market penetration and product acceptance.

Market Projections

Forecast for 2023-2030

The combined market for Alcohol 10% disinfectants and Dextrose 5% solutions is projected to grow at a CAGR of approximately 6% over the next seven years. The sterilization segment is expected to maintain dominant growth, driven by heightened hygiene standards post-pandemic.

• Alcohol 10% Market: Expected to reach USD 8 billion by 2025, with expansion into emerging markets. The development of organic and alcohol-based formulations with enhanced safety features will stimulate adoption.

• Dextrose 5% Market: Anticipated to see a valuation of USD 3.5 billion by 2025, with increasing application in pediatric and neonatal nutrition, alongside broader use in chronically ill patients.

Emerging Trends

• The integration of antimicrobial agents with alcohol solutions to combat resistant strains.
• Innovations in infusion stability and osmolarity regulation for Dextrose solutions.
• Expansion into wound care products incorporating alcohol and dextrose formulations.

Challenges to Market Growth

Regulatory delays, product recalls due to safety concerns, and competitive pressure from alternative therapies may temper projected growth. Additionally, rising consumer awareness about adverse effects of certain disinfectants could prompt demand for safer, bio-based alternatives.

Conclusion

The clinical trial ecosystem for Alcohol 10% and Dextrose 5% solutions indicates substantive progress toward optimized formulations with enhanced efficacy and safety profiles. Market trajectories reflect resilient growth fueled by global health initiatives, technological innovation, and expanding healthcare infrastructure, notably in emerging economies.

Organizations investing in R&D and regulatory compliance will position themselves favorably in this expanding market. Strategic partnerships, product diversification, and adherence to safety standards are crucial to capitalize on emerging opportunities.

Key Takeaways

• Clinical trials verify the efficacy and safety of Alcohol 10% and Dextrose 5% solutions, with ongoing innovation focusing on antimicrobial spectrum and infusion stability.

• The global market for these solutions is expected to grow at a CAGR of circa 6% through 2030, driven by infection control needs and increasing intravenous therapy demand.

• North America and Europe currently lead the market, but Asia-Pacific offers substantial growth potential due to expanding healthcare systems.

• Competition centers around product safety, formulation innovation, and compliance with strict regulatory standards.

• Strategic R&D, regulatory engagement, and market diversification are key to capturing future growth opportunities.

FAQs

1. What are the primary clinical applications of Alcohol 10% solutions?
   They are mainly used for surface disinfection, hand sanitization, and wound antisepsis, owing to their antimicrobial properties.

2. How does Dextrose 5% compare to higher concentration dextrose solutions in parenteral nutrition?
   Dextrose 5% minimizes hyperglycemia risk and is suitable for most patients, especially in critical care, whereas higher concentrations are reserved for increased caloric needs or specific patient conditions.

3. Are there safety concerns associated with prolonged use of Alcohol 10% solutions?
   Topical applications are generally safe, with minimal skin irritation. However, overuse can lead to dermatitis or hypersensitivity, emphasizing the importance of proper formulation and usage guidelines.

4. What regulatory challenges are faced by manufacturers of these formulations?
   Ensuring compliance with safety, efficacy, and quality standards set by agencies such as the FDA and EMA can delay product approval and market entry.

5. What future innovations are expected in Alcohol and Dextrose formulations?
   Antimicrobial combination formulations, improved infusion formulations with reduced osmolarity shocks, and environmentally friendly disinfectants are key areas of innovation.

---

References

[1] Smith et al., Journal of Antimicrobial Chemotherapy, 2022.
[2] Lee et al., Clinical Nutrition, 2021.
[3] Patel et al., Intensive Care Medicine, 2022.
[4] Allied Market Research, Disinfectants and Sanitizers Market Report, 2022.